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Introduction {#sec1}
============

The discovery of interleukin-17 (IL-17)-producing T helper 17 (Th17) cells has markedly changed our view of Th cell differentiation and T-cell-mediated pathogenesis of autoimmune diseases. A major research effort has been focused on the identification of signaling mediators that regulate Th17 cell differentiation, yet how Th17 cell function is initiated and maintained is an area of active research. Deregulated transforming growth-factor β (TGFβ) receptor (TGFβR) signaling has been implicated in Th17 cell autoimmune pathogenesis ([@bib6]; [@bib36]; [@bib53]). Among other factors, TGFβ critically promotes Th17-cell-mediated IL-17A responses ([@bib33]; [@bib55]; [@bib57]). A crucial role of TGFβ in experimental autoimmune encephalomyelitis (EAE) was highlighted by the finding that mice expressing dominant-negative TGFβRII confer resistance to EAE induction through a reduction in pathogenic Th17 cells ([@bib54]). Accordingly, elevated IL-17A levels have been detected in brain lesions and cerebrospinal fluid of individuals suffering from multiple sclerosis (MS), a Th17-cell-dependent inflammatory CNS-demyelinating disease ([@bib34]; [@bib38]), and of mice affected by EAE ([@bib13]; [@bib32]). TGFβ initiates its cellular function by binding to TGFβRII, which then activates TGFβRI activity through phosphorylation of several residues in the core of the GS domain. TGFβRI then propagates the signal by inducing SMAD2-3 phosphorylation, which subsequently leads to nuclear influx, SMAD2-3 DNA binding, and the transcriptional activation of several target genes ([@bib47]). However, the complete molecular mechanisms involved in TGFβR signaling, as well as potential Th-cell-selective mechanisms, remain elusive. The protein kinase C (PKC) family comprises nine mammalian isotypes of serine-threonine protein kinases that play distinct roles in signal-transduction pathways. Besides the PKCθ isotype ([@bib24]), key functions for the Ca^2+^-phospholipid-dependent PKCα isotype during T cell activation have been reported ([@bib16]; [@bib44]). Further evidence for the relevance of PKCα has been provided by the identification of polymorphisms associated with greater risk of MS ([@bib5]; [@bib46]). Despite this potential importance of PKCα in Th17-cell-mediated autoimmunity, the molecular aspects of PKCα function in Th17 cells and its physiological effector substrates have remained biochemically undefined. In the present study, we reveal a critical positive regulatory role of PKCα as a Th17-cell-selective intermediate of TGFβRI in directly regulating the kinase activity of TGFβRI, which itself activates SMAD2-3, maintains effective IL-17A responses, and thereby drives the pathogenesis of Th17-cell-mediated autoimmune diseases. This PKCα-TGFβRI kinase cooperation extends the paradigm of TGFβRI regulation in Th17 cell biology.

Results {#sec2}
=======

PKCα Positively Regulates IL-17A-Specific Th17 Cell Effector Function {#sec2.1}
---------------------------------------------------------------------

The examination of PKCα mRNA expression in different CD4^+^ Th cell subsets revealed that PKCα is substantially upregulated in in-vitro-differentiated Th17 cell cultures ([Figure 1](#fig1){ref-type="fig"}A). However, expression analysis of classical PKCβ, novel PKCθ, and PKCε, or atypical PKCι and PKCζ family members, revealed no Th17-cell-specific upregulation ([Figure S1](#mmc1){ref-type="supplementary-material"}A, available online). Expression-pattern analysis of key cytokines or transcription factors of wild-type (WT) Th cell types confirmed specific and efficient differentiation into the distinct effector Th cell lineages ([Figure S1](#mmc1){ref-type="supplementary-material"}B). The loss of PKCα preserved the effector responses of Th1-cell-mediated interferon-γ (IFN-γ), Th2-cell-mediated IL-4, and inducible regulatory T (iTreg)-cell-mediated IL-10 ([Figure 1](#fig1){ref-type="fig"}B). Strikingly, the secretion of IL-17A was notably reduced in PKCα*-*deficient (*Prkca*^*−/−*^) Th17 cells ([Figure 1](#fig1){ref-type="fig"}C). Of note, expression of the two main Th17-cell-linage-specific transcription factors, ROR-γt and ROR-α ([@bib26]; [@bib60]) ([Figure 1](#fig1){ref-type="fig"}D), as well as the transcription factors RUNX1, AHR, and IRF4 ([Figure S1](#mmc1){ref-type="supplementary-material"}C), which are related to Th17 cell development, was comparable between *Prkca*^*−/−*^ and WT Th17 cells. The levels of IL-23R and IL-12Rβ2 mRNA ([Figure S1](#mmc1){ref-type="supplementary-material"}D), the surface receptor expression of CCR6 ([Figure S1](#mmc1){ref-type="supplementary-material"}E), and the secretion responses of IL-21, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), TGFβ, and tumor necrosis factor α (TNF-α) ([Figure 1](#fig1){ref-type="fig"}E), which are all connected to Th17 cell effector functions ([@bib17]; [@bib30]), were not altered between PKCα-proficient and PKCα-deficient Th17 cells. A critical mechanism of effector Th17 cell establishment represents the IL-6-triggered activation of STAT3 ([@bib58]). However, immunoblot experiments showed no differences in (p)STAT3 levels between *Prkca*^*−/−*^ and WT CD4^+^ T cells, stimulated with either IL-6 or TGFβ alone or in combination, suggesting that PKCα does not play a role in the modulation of membrane-proximal signaling events downstream of the IL-6 receptor. In addition, the mRNA of IL-6Rα was equally expressed between both genotypes ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1G and data not shown). IL-17A and IL-17F, which are encoded within the same locus, are the most homologous IL-17 family members in that they have 50% identity in amino acid sequence ([@bib22]). However, in strict contrast to the barely detectable IL-17A mRNA expression ([Figure 1](#fig1){ref-type="fig"}F), IL-17F mRNA expression ([Figure 1](#fig1){ref-type="fig"}G) remained comparable between WT and *Prkca*^*−/−*^ Th17 cells. To experimentally reconfirm this selective regulation of IL-17A, but not IL-17F, we cocultured naive CD4^+^ OT-II T cells together with OVA~323-339~-primed dendritic cells (DCs) under Th17 cell conditions. As a result, when compared to WT OT-II Th17 cells, *Prkca*^*−/−*^ OT-II Th17 cells differentiated into a strongly reduced population of IL-17A^+^IL-17F^−^ cells but an equal population of IL-17A^−^IL-17F^+^ cells ([Figure 1](#fig1){ref-type="fig"}H and [Figure S1](#mmc1){ref-type="supplementary-material"}H). As a control, defective IL-17A production in *Prkca*^*−/−*^ Th17 cells did not correlate with an increased conversion to Th1 or iTreg cells under Th17-cell-polarizing conditions in that they displayed no increase in T-BET or FOXP3, the signature transcription factors of Th1 and iTreg cells, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The results were attributable neither to survival defects nor to a hindered proliferation of *Prkca*^*−/−*^ Th17 cells ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C and data not shown). Taken together, these results indicate that the absence of PKCα leads to a profound selective inhibition of Th17 cell effector function at the transcriptional level of IL-17A.

PKCα Deficiency Protects against EAE Induced by Myelin Oligodendrocyte Glycoprotein~35-55~ {#sec2.2}
------------------------------------------------------------------------------------------

These observations prompted us to analyze the potential role of PKCα in Th17-cell-based inflammatory immune pathogenesis in vivo. Thus, we determined the susceptibility of *Prkca*^*−/−*^ mice to EAE. We immunized WT and *Prkca*^*−/−*^ mice with myelin oligodendrocyte glycoprotein~35-55~ (MOG~33-55~) and monitored them for clinical signs of EAE. As expected, all WT mice developed EAE; in contrast, *Prkca*^*−/−*^ mice displayed a slightly delayed onset, indicating that priming events might be altered. Moreover, the absence of PKCα almost completely inhibited EAE disease development ([Figure 1](#fig1){ref-type="fig"}I and [Table 1](#tbl1){ref-type="table"}). At the peak of clinical disease signs (day 14), infiltrating CD4^+^ cells from the brain, spinal cord, and draining lymph nodes were analyzed by flow cytometry. The absolute numbers of CD4^+^ mononuclear cells ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and the percentage of CD4^+^ROR-γt^+^ cells ([Figure 1](#fig1){ref-type="fig"}J) remained within a normal range between both genotypes. Although WT and *Prkca*^*−/−*^ Th17 cells generated in vitro produce only marginal amounts of IFN-γ ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), Th17 cells generated in vivo often coproduce IFN-γ during EAE ([@bib1]; [@bib20]; [@bib26]). However, IL-17A^+^ and IFN-γ^+^ CD4^+^ CNS-infiltrating cells, as well as IL-17A^+^IFN-γ^+^ CD4^+^ CNS-infiltrating cells, were significantly reduced in *Prkca*^*−/−*^ mice compared to WT mice ([Figure 1](#fig1){ref-type="fig"}K and right panels). Consistently, ex vivo recall-response analysis at the priming phase of the disease (day 10 after MOG~35-55~ immunization) revealed strongly decreased values of both IL-17A and IFN-γ ([Figure 1](#fig1){ref-type="fig"}L). GM-CSF is also known to play a role during EAE ([@bib40]), yet its levels remained unaffected in EAE-recall assays ([Figure 1](#fig1){ref-type="fig"}M). Strikingly, severely increased levels of IL-2 in MOG~35-55~-antigen-restimulated *Prkca*^*−/−*^ splenocytes were detected ([Figure 1](#fig1){ref-type="fig"}N). Collectively, these data demonstrate that PKCα is essential for the priming and effector phases of EAE.

It has been shown that CD4^+^CD25^+^FOXP3^+^ Treg cells contribute to EAE disease amelioration by suppressing autoreactive effector Th cell expansion ([@bib43]). By observing reduced FOXP3^+^ cell infiltrates in *Prkca*^*−/−*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}G), we excluded the involvement of FOXP3^+^ Treg cells in the EAE protection of *Prkca*^*−/−*^ mice during acute disease. Consistently, and again in contrast to analysis of Th17 cells, phenotypical analysis of *Prkca*^*−/−*^ iTreg cells revealed a dispensable role of PKCα in iTreg cell effector responses, as reflected by FOXP3 mRNA expression ([Figure S2](#mmc1){ref-type="supplementary-material"}H), the suppressive capabilities in dampening Th cell effector responses, and the unaltered TGFβR-SMAD2-3 activation responses (data not shown). Furthermore, we could demonstrate that under all investigated doses of TGFβ during iTreg cell differentiation, the fraction of CD4^+^CD25^+^FOXP3^+^ cells was comparable between the genotypes ([Figure S2](#mmc1){ref-type="supplementary-material"}I). Of note, no developmental defect was detected in the generation of CD4^+^CD25^+^FOXP3^+^ natural regulatory T (nTreg) cells in the absence of PKCα ([Figure S2](#mmc1){ref-type="supplementary-material"}J). Collectively, these results provide evidence that PKCα is not required to effectively induce iTreg cell functions and reveal an unexpected, subset-selective role for PKCα in Th17 cells.

To evaluate a potential CD4^+^ T-cell-intrinsic function of PKCα in vivo, we transferred ex vivo MOG~35-55~-antigen-restimulated, CD4^+^-enriched, Th17-differentiated cells from either MOG~35-55~-immunized WT or *Prkca*^*−/−*^ mice into syngeneic WT recipient mice. Prior to the adoptive cell transfer, the extent of MOG~35-55~-specific Th17 cell differentiation was validated. A severely impaired antigen-specific immune response, featured by diminished frequencies of IL-17A^+^IFN-γ^−^, IL-17A^−^IFN-γ^+^, and IL-17A^+^IFN-γ^+^ CD4^+^ T cells, was demonstrated in the *Prkca*^*−/−*^ cells ([Figures 2](#fig2){ref-type="fig"}A and 2B). In addition, analysis of culture supernatants demonstrated considerably reduced IL-17A and IFN-γ levels in *Prkca*^*−/−*^ cells ([Figure 2](#fig2){ref-type="fig"}C). However, the total population of CD4^+^ROR-γt^+^ cells prior to adoptive cell transfer was comparable between genotypes ([Figures 2](#fig2){ref-type="fig"}D and 2E), excluding an artifact due to lower CD4^+^ Th17 cell frequencies between genotypes in the inoculum. The development of EAE disease severity in mice that received *Prkca*^*−/−*^ CD4^+^ Th17 cells was markedly reduced, and the onset of clinical EAE signs was significantly delayed in these mice compared to those animals receiving WT cells ([Figure 2](#fig2){ref-type="fig"}F and [Table 2](#tbl2){ref-type="table"}). These observations indicate that MOG~35-55~-specific CD4^+^ Th17 cells from *Prkca*^*−/−*^ mice are unable to efficiently induce EAE in recipient mice. DCs are critical accessory cells during EAE and produce inflammatory cytokines, which are required for Th17 cell development in vivo ([@bib30]; [@bib53]). In order to exclude the possibility that impaired Th17 cell development in *Prkca*^*−/−*^ mice is caused by a defect in DCs, we evaluated the functionality of *Prkca*^*−/−*^ DCs. The critical DC markers CD86 and CD40 were appropriately expressed on the surface of *Prkca*^*−/−*^ DCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Additionally, lipopolysaccharide (LPS)-stimulated *Prkca*^*−/−*^ DCs did not show impaired IL-6, IFN-γ, or TNF-α responses ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Moreover, a coculture of naive WT or *Prkca*^*−/−*^ CD4^+^ OT-II T cells together with OVA~323-339~-pulsed WT or *Prkca*^*−/−*^ DCs indicated that *Prkca*^*−/−*^ DCs were capable of supporting Th17 cell development normally. However, the percentage of the CD4^+^IL-17A^+^ T cell population of *Prkca*^*−/−*^ mice was strongly reduced regardless of the origin of the cocultured DCs ([Figure 2](#fig2){ref-type="fig"}G). Although we cannot exclude the existence of a Th17-cell-extrinsic role of PKCα, these experiments validate PKCα as a critical player in Th17-cell-driven neuroinflammatory autoimmune disease.

PKCα Is an Essential Regulator of the TGFβR-SMAD-Signaling Pathway {#sec2.3}
------------------------------------------------------------------

To elucidate the mechanistic basis of the decreased IL-17A expression found in *Prkca*^*−/−*^ Th17 cells, we cultured WT and PKCα-deficient naive CD4^+^ T cells under distinct Th17 cell cytokine milieus. The stimulations that were performed in the absence of TGFβ did not reveal gross differences in IL-17A expression. However, when TGFβ was applied in combination with IL-6, IL-23, or IL-1α, *Prkca*^*−/−*^ Th17 cells, compared to WT Th17 cells, exhibited remarkably reduced IL-17A secretion responses ([Figure 3](#fig3){ref-type="fig"}A), indicating defective TGFβR signaling. This finding was secondary to neither downregulated expression of TGFβRI and TGFβRII mRNA nor reduced TGFβRI and TGFβRII protein expression ([Figures 3](#fig3){ref-type="fig"}B--3D). Remarkably, the observed reduced TGFβR-mediated IL-17A-secretion response in *Prkca*^*−/−*^ Th17 cells was especially prominent at high TGFβ concentrations ([Figure 3](#fig3){ref-type="fig"}E). However, IL-17F remained unaffected under these conditions ([Figure 3](#fig3){ref-type="fig"}F). Strikingly, confocal-microscopy analysis of endogenously stained PKCα and TGFβRI identified a constitutive and TGFβ-inducible colocalization of these two proteins in primary human CD4^+^ peripheral-blood mononuclear cells (PBMCs) ([Figures 3](#fig3){ref-type="fig"}G and 3H). This PKCα-TGFβRI-colocalization complex peaked at 5 minutes and remained elevated for at least 1 hour of TGFβ stimulation. As a control, neither PKCα nor TGFβRI colocalized with the transmembrane IL-6R subunit gp130 ([Figures 3](#fig3){ref-type="fig"}I and 3J). Furthermore, a constitutive and TGFβ-inducible physical interaction between the endogenous PKCα and TGFβRI proteins in primary T cells was confirmed by coimmunoprecipitation ([Figure 3](#fig3){ref-type="fig"}K). Interestingly, PKCα mRNA expression in CD4^+^ T cells was inducible by TGFβ ([Figure 3](#fig3){ref-type="fig"}L). However, mRNA expression of PKCθ under similar conditions remained unaffected (data not shown). Several groups showed that TGFβ directly upregulates PKCα protein ([@bib11]; [@bib64]) and mRNA levels ([@bib15]; [@bib45]). To investigate the PKCα domains that are capable of physically interacting with TGFβRI, we cotransfected the HIS~6~-tagged WT PKCα, the constitutively active PKCα mutant, or the catalytic subdomain of PKCα with a FLAG-tagged WT TGFβRI expression vector in human embryonic kidney (HEK)293T cells. Here, pulldown assays showed that the catalytic fragment of PKCα is sufficient to bind TGFβRI, suggesting a kinase-substrate relationship ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

TGFβRI Is a Direct Substrate of PKCα {#sec2.4}
------------------------------------

By using in vitro kinase assays, we showed that PKCα is able to induce TGFβRI phosphorylation. Here, inclusion of TGFβRII, together with PKCα, led to a synergistic phosphorylation of TGFβRI. In addition, TGFβRI phosphorylation was reduced by a PKCα-specific inhibitor ([Figure 4](#fig4){ref-type="fig"}A). Predicting PKC-mediated phosphorylation sites led to the identification of T200 on TGFβRI as a bona fide candidate PKC-mediated phosphorylation site. The experimental investigation indicated that the T200WT TGFβRI peptide, but not the T200V mutant motif, was phosphorylated by PKCα ([Figure 4](#fig4){ref-type="fig"}B). TGFβRII additively acts with PKCα to induce phosphorylation of T200WT, but not the T200V mutant, TGFβRI motif. Next, we evaluated the presence of this phosphosite on endogenous TGFβRI by using a (p)T200-site-specific antiserum that was raised for this investigation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Both immunoblot ([Figure 4](#fig4){ref-type="fig"}C) and intracellular flow cytometry showed that phosphorylation of T200 on TGFβRI was induced by TGFβ in WT, but not *Prkca*^*−/−*^, CD4^+^ T cells ([Figures 4](#fig4){ref-type="fig"}D and 4E). Although we cannot exclude the existence of additional PKCα-mediated phosphorylation sites, the above results from the use of the (p)T200 TGFβRI antibody suggest that T200 on TGFβRI is a PKCα-mediated phosphorylation site in intact T cells. Notably, the T200 site is in close proximity to the established binding site of the immunophilin FKBP1A on TGFβRI. During steady state, FKBP1A bound to TGFβRI counteracts ligand-independent unspecific phosphorylation of TGFβRI by TGFβRII. However, TGFβ-ligand-induced receptor activation causes the release of FKBP1A from TGFβRI ([@bib10]; [@bib47]). Cotransfection with constitutively active PKCα significantly diminished binding of FKBP1A to the WT TGFβRI ([Figure 4](#fig4){ref-type="fig"}F; lanes 1 and 6), which was rescued when the phosphorylation-defective T200V TGFβRI mutant was cotransfected ([Figure 4](#fig4){ref-type="fig"}F; lanes 6 and 8). Moreover, the phosphomimic T200D TGFβRI mutant completely failed to bind FKBP1A ([Figure 4](#fig4){ref-type="fig"}F; lanes 2 and 7). As a control, T204 alterations in TGFβRI did not show this effect. These data suggest that phosphorylation of T200 on TGFβRI by PKCα might lead to an induced displacement of FKBP1A from the TGFβRI. Collectively, these data suggest a physical and functional TGFβRI-PKCα interaction that might regulate efficient TGFβRI kinase-activation responses.

PKCα Does Not Play a Role in Noncanonical TGFβ-Mediated Signaling Pathways {#sec2.5}
--------------------------------------------------------------------------

TGFβ is known to also signal via noncanonical pathways ([@bib41]). However, to this point, we have been unable to detect a substantial TGFβ-induced activation of the noncanonical TGFβ-signaling pathways p38 mitogen-activated protein (MAP) kinase, stress-activated protein kinase (SAPK)/Jun amino-terminal kinase (JNK), extracellular-signal-regulated kinases 1 and 2 (ERK1/2), or protein kinase B (PKB or AKT) in primary T cells ([Figures S5](#app2){ref-type="sec"}A--S5H), consistent with observations of other groups ([@bib8]; [@bib9]). Nevertheless, we observed no difference in the activation levels between WT and *Prkca*^*−/−*^ cells. Furthermore, SMAD-independent TGFβ-mediated downregulation of eomesodermin ([@bib23]) remains unaffected in the absence of PKCα ([Figure S5](#mmc1){ref-type="supplementary-material"}I).

PKCα Is a Critical Signaling Intermediate of the SMAD-Dependent TGFβRI-Signaling Pathway {#sec2.6}
----------------------------------------------------------------------------------------

The investigation of the canonical, SMAD-dependent TGFβRI-signaling pathway led to the striking observation that the phosphorylation of both SMAD2 and SMAD3 is impaired in *Prkca*^*−/−*^ CD4^+^ T cells ([Figures 5](#fig5){ref-type="fig"}A and 5C). In addition, the treatment of WT CD4^+^ T cells with a PKCα-specific inhibitor led to a complete phenocopy of *Prkca*^*−/−*^ cells, indicating that the PKCα catalytic activity is required to activate the canonical TGFβRI-SMAD2-3 pathway ([Figures 5](#fig5){ref-type="fig"}B and 5C). Similarly, transfection of Jurkat T cells with a kinase-dead PKCα mutant construct repressed the induction of a SMAD-dependent promoter luciferase reporter ([Figure 5](#fig5){ref-type="fig"}D). At the same time, both WT and *Prkca*^*−/−*^ naive CD4^+^ T cells expressed similar SMAD2, SMAD3, and SMAD4 levels ([Figure 5](#fig5){ref-type="fig"}E and data not shown). By using band-shift assays, we identified a strong defect in SMAD2-3 DNA-binding activity in both genetically deleted and pharmacologically PKCα-inhibited cells ([Figures 5](#fig5){ref-type="fig"}F--5H). Taken together, our data suggest that PKCα acts as a positive regulator of SMAD2-3-mediated TGFβ signaling in T cells and that its deletion results in reduced sensitivity to the biologic effects of TGFβ. Interestingly, the SBE has been located upstream of the *Il2* promoter, which is important for SMAD-mediated transcriptional suppression of IL-2 ([@bib50]). Moreover, it was demonstrated that TGFβ suppresses IL-2 production of T cells ([@bib7]) in a SMAD3-dependent manner ([@bib39]). In order to elucidate the connection between the impaired TGFβ-mediated SMAD-signaling cascade and the severely reduced IL-17A Th17 cell effector responses in the absence of PKCα, we investigated IL-2 amounts. Interestingly, we observed substantially elevated IL-2 amounts in Th17 cell cultures ([Figure 5](#fig5){ref-type="fig"}I), as well as in MOG~35-55~ EAE-recall samples ([Figure 1](#fig1){ref-type="fig"}N) in the absence of PKCα. A recent study ([@bib61]) supports a model in which the balance of IL-6-induced STAT3- and IL-2-triggered STAT5-DNA-binding capabilities directly dictates the outcome of IL-17A production. Indeed, by using band-shift assays, we observed a severely impaired STAT binding to the minimal *Il17a* promoter region in *Prkca*^*−/−*^ CD4^+^ T cells, stimulated under Th17-cell-polarizing conditions (TGFβ + IL-6) ([Figure 5](#fig5){ref-type="fig"}J). Furthermore, ChIP analysis revealed a notably reduced STAT3 DNA binding to the same *Il17a* promoter region in WT Th17 cells treated with a PKCα-specific inhibitor (data not shown), as well as in *Prkca*^*−/−*^ Th17 cells ([Figure 5](#fig5){ref-type="fig"}K).

Discussion {#sec3}
==========

TGFβR signaling plays an essential role in the generation of iTreg and Th17 cells, yet little is known about whether TGFβR-triggered pathways might make use of linage-specific activators of TGFβR signaling. Here, we report that CD4^+^ T cells lacking PKCα function exhibit a specific Th17 cell defect in vitro and during neuroinflammatory disease in vivo. Our data of the hyposusceptibility of *Prkca*^*−/−*^ mice to EAE induction and the substantial reduction of IL-17A^+^ and IFN-γ^+^ CNS cell infiltrates demonstrate that PKCα is critical for the control of IL-17A transcription. Supporting our findings of IL-17A^+^IFN-γ^+^ cells in *Prkca*^*−/−*^ mice during EAE, there exists sophisticated evidence that Th17 cells have considerable plasticity toward a Th1 cell phenotype in EAE by producing both IL-17A and IFN-γ ([@bib26]; [@bib63]). With the use of mouse systems tracking reporter Th cell fate, it has been shown that IL-17A-producing cells are reprogrammed to produce both IL-17A and IFN-γ or even IFN-γ alone during EAE ([@bib20]; [@bib31]). Thus, we speculate that this robust IFN-γ-production defect observed in *Prkca*^*−/−*^ Th17 cells during EAE disease progression is secondary to the IL-17A defect.

Mice deficient in IL-17A exhibit delayed onset, reduced scores of maximum severity, ameliorated histological changes, and early recovery of EAE ([@bib25]; [@bib29]; [@bib42]; [@bib59]). Moreover, it has been shown that in vivo neutralization of IL-17A significantly reduces the severity of EAE ([@bib21]; [@bib29]; [@bib52]). However, there exist some contradictory data on the relative importance of IL-17A during EAE ([@bib14]; [@bib18]), but the consensus view is that IL-17A clearly plays a pathogenic role in EAE and MS. Nevertheless, we cannot exclude additional PKCα-mediated effects (next to IL-17A) for the apparent EAE benefit in *Prkca*^*−/−*^ mice.

We observed that the decreased IL-17A levels do not correlate with a decreased ROR-γt expression in *Prkca*^*−/−*^ Th17 cells. Consistently, changes in IL-17A expression can be independent of ROR-γt expression, as observed in other studies ([@bib2]; [@bib28]; [@bib51]).

Interestingly, we observed a reduced population of FOXP3^+^ cells in *Prkca*^*−/−*^ CNS tissues during acute EAE. This counterintuitive finding might merely reflect a reduced recruitment of FOXP3^+^ iTreg cells as a result of the curtailed inflammatory stimulus in *Prkca*^*−/−*^ mice. Interestingly, several reports ([@bib12]; [@bib54]) underpinned a potential pathologic function of iTreg cells by showing that FOXP3^+^ iTreg cells empowered rather than inhibited Th17 cell differentiation during chronic inflammatory conditions in vivo. Thus, we could speculate that the reduced presence of FOXP3^+^ cells in CNS tissues of *Prkca*^*−/−*^ mice during EAE even represents a beneficial, though until this point undefined, mechanism. Our results support the notion that PKCα is not required to effectively induce iTreg cell functions and reveal an unexpectedly selective role for PKCα in TGFβR signaling in Th17 cells.

Mechanistically, we have shown that PKCα deficiency renders T cells less sensitive to TGFβ-induced SMAD2-3 activation. Of note, the cellular role of SMAD2-3 signaling in Th17 and iTreg cells is not without controversy in the literature given that two studies showed that SMAD2 is especially important for the optimal induction of Th17 cells ([@bib35]; [@bib48]), whereas another report ([@bib37]) indicated that SMAD3-activation defects increase Th17 cell effector functions. However, in agreement with our investigations, a recent study demonstrated that the enhanced generation of Th17 cells is associated with increased TGFβ-induced SMAD2-3 activation ([@bib8]).

Th17 cell commitment represents a dynamic balance between the DNA-binding of STAT3 and STAT5 to sites along the single *Il17a*--*Il17f* locus. Furthermore, STAT5 DNA binding is associated with displacement of STAT3 within the *Il17a* promoter region ([@bib61]). Here, we provide strong experimental data that the absence of PKCα abrogates STAT3 DNA accessibility to the minimal *Il17a* promoter region in Th17 cells. Thus, it is tempting to speculate that in *Prkca*^*−/−*^ Th17 cells, IL-2 hyperproduction, which is secondary to the defects in SMAD2-3 activation, might lead to increased efficiency of STAT5 DNA binding, thereby displace STAT3 from this locus, and ultimately result in the observed inhibition of IL-17A transcription. Importantly, another study ([@bib8]) has also suggested that a main function of TGFβ in early Th17 cell differentiation might be the inhibition of IL-2-mediated suppression of Th17 cell generation.

Given the selective IL-17A expression defect, which does not affect IL-17F expression, in *Prkca*^*−/−*^ Th17 cells, it is important to mention that the *Il17a* promoter is established to be primarily responsive to STAT3, whereas the *Il17f* promoter is largely responsive to ROR-γt ([@bib49]). Accordingly, it has been demonstrated that at high IL-6 concentrations, IL-17F, in strict contrast to IL-17A, is insensitive to IL-2-mediated inhibition ([@bib61]). Given the present data, we can hypothesize that this selective PKCα-dependent Th17 cell defect during TGFβR signaling is due to constrained STAT3 binding to the *Il17a* promoter.

In this study, direct regulation of the canonical TGFβRI-SMAD pathway by PKCα appeared to be mediated at the level of T200 phosphorylation on TGFβRI. Intriguingly, the T200V alteration has been identified to severely inhibit TGFβRI kinase activity and consequently TGFβ-dependent activation responses ([@bib56]). However, the protein kinase that is responsible for the physiological phosphorylation of this candidate phosphosite has not been defined to date. Given the obtained results, one possible function of PKCα might be to modulate FKBP1A binding on TGFβRI, and the T200 phosphoswitch, located within the critical interaction surfaces of these two binding partners, might alter local electrostatic potential to perturb the intermolecular interaction with FKBP1A, required for effective negative TGFβRI kinase regulation.

Collectively, this study extends the paradigm underlying TGFβRI activation in the efficient generation of Th17 cell immune responses. Consistent with human genetic data that link polymorphisms of *PRKCA* (encoding PKCα) to the Th17-cell-based pathogenesis of MS ([@bib5]; [@bib46]), our findings reveal an essential immunomodulatory function of PKCα. Intriguingly, because PKC inhibitors are in clinical trials ([@bib4]), our findings could provide a rational mechanistic basis for the treatment of certain Th17-cell-mediated immune pathologies.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

The generation of the *Prkca*^*−/−*^ mice was described previously ([@bib44]). All animal studies complied with the current laws and were approved by the authors' respective institutional review boards.

Th Cell Differentiation {#sec4.2}
-----------------------

Naive CD4^+^ T cells were isolated with a CD4^+^CD62L^hi^ T cell isolation kit II (Miltenyi Biotec), and the Th-cell-subset differentiation (3 days) was performed in RPMI or IMDM (for Th17 cell differentiation) as previously described ([@bib19]). In brief, the Th-cell-neutral (Th0) conditions contained neither exogenous cytokines nor blocking antibodies. The other conditions were as follows: Th1 = mIL-12 (10 ng/ml) and αIL-4 (5 μg/ml); Th2 = IL-4 (10 ng/ml), αIL-12 (5 μg/ml), and IFN-γ (5 μg/ml); Th17 = TGFβ (5 ng/ml), IL-6 (40 ng/ml), IL-1α (20 ng/ml), αIL-4 (2 μg/ml), and αIFN-γ (2 μg/ml); and iTreg = TGFβ (10 ng/ml), IL-2 (10 ng/ml), αIFN-γ (5 μg/ml), αIL-12 (5 μg/ml), and αIL-4 (5 μg/ml). Naive CD4^+^ OT-II T cells were stimulated with 2.5 × 10^5^ LPS (100 ng/ml)-activated splenic CD11c^+^ DCs (DC:T cell = 1:4) and pulsed with 1 μM OVA-peptide~323-339~ (Genscript) in the presence of Th17-cell-polarizing cytokines for 3 days.

Analysis of Cytokine Production {#sec4.3}
-------------------------------

The cytokine amount in culture supernatants was determined with BioPlex multianalyte technology (Biorad) on day 3 of Th cell differentiation according to the manufacturer's instructions. For IL-4 and TGFβ analysis in Th2 and Th17 cell cultures, respectively, cells were washed after 3 days of differentiation and restimulated with 2 μg/ml plate-bound CD3 antibody for 24 hr in serum-free X-vivo 20 medium. The supernatant was used for cytokine analysis.

EAE Assay and Preparation of CNS Mononuclear Cells {#sec4.4}
--------------------------------------------------

The EAE assay and the preparation of CNS mononuclear cells have been previously described ([@bib19]).

Passive Adoptive EAE {#sec4.5}
--------------------

The general procedure was adapted, with minor modifications, to reports in [@bib3], [@bib27], and [@bib29]. Splenocyte suspensions were generated from MOG~35-55~-immunized (day 10) WT, *Prkca*^*−/−*^, or WT PBS-treated control mice. Splenocytes were restimulated with 25 μg/ml MOG~35-55~ under Th17-cell-polarizing conditions for 3 days. CD4^+^ T cells were purified with a MACS (Miltenyi Biotec) kit, and 1.5 × 10^7^ cells were transferred into healthy WT recipient mice (intraperitoneally \[i.p.\]). In addition, pertussis toxin (Sigma; 200 ng/mouse) was administered i.p. on the day of the adoptive transfer and 48 hr later. Signs of EAE were assigned scores on a scale of 0--4 ([@bib19]).

Coimmunoprecipitation Analysis {#sec4.6}
------------------------------

The coimmunoprecipitation analysis was described previously ([@bib16]). In brief, a total of 5 × 10^7^ murine CD3^+^ T cells were lysed, precleared, and incubated with 2 μg of PKCα antibody (Millipore) overnight. Unspecific IgG Ab was used as a negative control. Thereafter, samples were incubated with protein G sepharose (Amersham-Pharmacia), washed in lysis buffer, and resolved by SDS-PAGE.

Gel Shift Assay {#sec4.7}
---------------

NEs were harvested from 1 × 10^7^ to 2 × 10^7^ CD4^+^ T cells according to standard protocols. In brief, CD4^+^ T cells were isolated with the CD4^+^ T cell Isolation Kit (Miltenyi Biotec) and rested for 1.5 hr in X-vivo 20 (37°C, 5% CO~2~); this was followed by various stimulation conditions (as indicated). Cells were resuspended in 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), and protease inhibitors. Cells were incubated on ice for 15 min. NP-40 was then added to a final concentration of 0.6%, the cells were vigorously mixed, and the mixture was centrifuged for 5 min at 2,300 rpm × g. The nuclear pellets were resuspended in 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and protease inhibitors, and the tubes ware rocked for 30 min at 4°C. After centrifugation at 13,400 rpm × g, the supernatants were collected and stored at −80°C for further analysis. Nuclear protein extracts (2--7 μg) were incubated in binding buffer with the end-labeled, double-stranded oligonucleotide SBE probe (SBE consensus oligonucleotide \[sc-2603\]: 5′-AGTATGTCTAGACTGA-3′) as described previously ([@bib28]). The following WT and mutated oligonucleotides were used, and the core binding motifs for STAT are underlined for the minimal *Il17a* promoter: 5′-TCTGTTCAGC[TCC]{.ul}CAA[GAA]{.ul}GTCATGC[TTC]{.ul}TTTGCATAGT[GAA]{.ul}C[TTC]{.ul}TGCC-3′ (Stat) and 5′-TCTGTACAGCTCCCAAGCAGTCATGCTACTTTGCATAGTGTACTGCTGCC-3′ (Stat mu). The band shifts were resolved on a 5% polyacrylamide gel.

RNA Transcript Analysis by qRT-PCR {#sec4.8}
----------------------------------

The gene-expression analysis has been previously described ([@bib28]). For qRT-PCR analysis, cells were restimulated with plate-bound CD3 antibody (2 μg/ml) for 4 hr. Data were normalized to GAPDH mRNA and are presented relative to Th0 levels.

Statistical Analysis {#sec4.9}
--------------------

The p values were calculated with an unpaired Student's t test. Significant differences are indicated as ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.

Supplemental Information {#app2}
========================
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![PKCα Is a Positive Regulator of Th17 Cell Effector Functions In Vitro and In Vivo\
Naive CD4^+^ T cells were cultured under indicated Th-cell-polarizing conditions for 3 days. Error bars represent ± SEM. Data in (A)--(G) were derived from at least three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. (See also [Figure S1](#mmc1){ref-type="supplementary-material"}).\
(A) PKCα mRNA is highly expressed in Th17 cells.\
(B--D) Production of IFN-γ (B, left), IL-4 (B, middle), IL-10 (B, right), and IL-17A (C) was determined. Immunoblotting (IB) (C, inset) indicates the efficient deletion of PKCα in CD4^+^ T cells. The mRNA expression of ROR-γt (D, left) and ROR-α (D, right) was analyzed by quantitative RT-PCR (qRT-PCR).\
(E) Amounts of IL-21, IL-22, GM-CSF, TGFβ, and TNF-α were analyzed.\
(F and G) The mRNA expression of IL-17A (F) and IL-17F (G) was analyzed by qRT-PCR.\
(H) *Prkca*^+/+^ or *Prkca*^−/−^ naive CD4^+^ OT-II T cells were stimulated with OVA~323-339~-pulsed DCs under Th17-cell-polarizing conditions. Intracellular IL-17A and IL-17F (Vα2TCR^+^ gated) were analyzed by flow cytometry. Data were derived from two independent experiments of three mice per group.\
(I) Disease time course combining three independent experiments of EAE in WT (n = 22) or *Prkca*^−/−^ (n = 19) mice.\
(J and K) Mononuclear cells were isolated from the brain, spinal cord, and draining lymph nodes and were stained for intracellular ROR-γt (J) or IL-17A (K) and IFN-γ (CD4^+^ gated). Representative fluorescence-activated cell sorting (FACS) plots (CD4^+^-gated) of IL-17A- and IFN-γ-expressing CNS-infiltrating cells in WT and *Prkca*^−/−^ mice are displayed (right panel). Data were derived from three mice per group per experiment from two independent experiments.\
(L--N) Amounts of IL-17A (L, left), IFN-γ (L, right), GM-CSF (M), and IL-2 (N) in the supernatant of EAE-mice splenocytes restimulated with MOG~35-55~. Data were obtained from five separate mice per group.](gr1){#fig1}

![PKCα-Deficient Mice Are Resistant to EAE in a Passive Adoptive-Transfer Model\
For adoptive EAE, draining lymph-node cells and splenocytes from MOG~35-55~-immunized WT, *Prkca*^−/−^, or PBS-treated WT (control) mice were restimulated with MOG~35-55~ in the presence of Th17-cell-polarizing cytokines for 3 days. Data in (A)--(E) were derived from five mice per group. (See also [Figure S2](#mmc1){ref-type="supplementary-material"}). Error bars in (B), (C), (E), and (F) represent ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
(A and B) Representative FACS dot plots of IL-17A^+^ and IFN-γ^+^ cells (CD4^+^ gated) are displayed in (A), and the quantification is shown in (B).\
(C) IFN-γ (left) and IL-17A (right) levels were measured.\
(D and E) Representative FACS dot plots of ROR-γt^+^ cells (CD4^+^ gated) are displayed in (D), and the quantification is shown in (E).\
(F) Disease time course of adoptive EAE in WT recipients, reconstituted with Th17-cell-polarized WT (n = 4), *Prkca*^−/−^ (n = 4), or control CD4^+^-enriched (n = 2) cells. Of note, control mice injected with cells from PBS-injected WT mice and stimulated in vitro for 3 days with MOG~33-35~ under Th17-cell-polarizing conditions did not show any disease signs.\
(G) Naive CD4^+^ OT-II T cells were stimulated with OVA~323-339~-pulsed DCs under Th17-cell-polarizing conditions. Cells were stained for Vα2TCR and intracellular IL-17A and analyzed by flow cytometry. Representative FACS plots of two independent experiments of three mice per group are shown.](gr2){#fig2}

![Physical Interaction between PKCα and TGFβRI\
(A) IL-17A levels were assessed of cells differentiated with the indicated Th17-cell-favoring cytokines.\
(B) The mRNA transcript levels of TGFβRI and TGFβRII of naive CD4^+^ T cells were determined with qRT-PCR. The results are presented relative to WT levels.\
(C) Flow-cytometry analysis of TGFβRII surface expression of naive CD4^+^ T cells. A representative FACS histogram (CD4^+^ gated) and quantification of the mean fluorescence intensity (MFI) per cell are shown.\
(D) The expression level of TGFβRI in CD4^+^ T cells, stimulated with TGFβ as indicated, was detected by IB. One representative blot from at least four independent experiments that yielded similar results is shown.\
(E and F) Levels of IL-17A (E) and IL-17F (F) were assessed of cells differentiated with the indicated TGFβ concentrations after 3 days of Th17 cell differentiation.\
(G and H) Representative confocal immunofluorescence (G) and quantification (H) of the colocalization of PKCα and TGFβRI in untreated (ctr) or TGFβ-treated human CD4^+^ PBMCs.\
(I and J) Representative single confocal section overlays of cells stimulated with TGFβ (2 min) (I). Quantitative colocalization analysis is shown in (J).\
(G and I) Colors are as follows: green, PKCα; red, TGFβRI; yellow, merged; and purple, gp130. The scale bars represent 5 μm. All pixels colocalized are represented as white spots.\
(K) Endogenous binding between PKCα and TGFβRI in CD3^+^ T cells. TGFβRI antibody or normal IgG antibody (control IP) was used for the immunoprecipitation and analyzed by IB with a PKCα antibody.\
(L) Naive WT CD4^+^ T cells were stimulated with TGFβ and analyzed for expression of PKCα.\
Data in (A)--(C), (E), and (F) were derived from two independent experiments of three to four mice per group. Data in (D), (L), and (K) were derived from at least three independent experiments. Error bars in (A)--(C), (E), (F), (H), (J), and (L) represent ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. (See also [Figure S3](#mmc1){ref-type="supplementary-material"}).](gr3){#fig3}

![PKCα Phosphorylates T200 on TGFβRI\
(A) Kinase assays of the glutathione S-transferase (GST) fusion protein of the cytoplasmic subdomain of TGFβRI (amino acids 148--503) were incubated with recombinant PKCα and TGFβRII as indicated. Phosphorylation was detected by autoradiography. The GST-antibody immunoblot (lower panel) confirmed equal loading.\
(B) The phosphorylation rates of T200WT and T200V mutant motifs were measured by the incorporation of ^32^P~i~ from γ^32^P-ATP incubated with PKCα and/or TGFβRII kinases. The following abbreviation is used: cpm, counts per minute.\
(C) Naive CD4^+^ T cells were stimulated with TGFβ as indicated. TGFβ-inducible phosphorylation of T200 on TGFβRI was observed in WT cells, but not *Prkca*^−/−^ cells, as shown by a representative IB.\
(D and E) The intracellular induction by (p)T200 on TGFβRI with the (p)T200-specific antibody and the quantification of the percent induction of MFI are shown. In (E), the error bars represent ± SEM. ^∗^p \< 0.05.\
(F) Cotransfection of Jurkat T cells with constitutively active A25E PKCα significantly diminished binding of FKBP1A to the WT TGFβRI, but not the neutral-exchange T200V mutant of TGFβRI. Representative data were derived from at least two independent experiments.\
(See also [Figure S4](#mmc1){ref-type="supplementary-material"}).](gr4){#fig4}

![The Activation of SMAD2 and SMAD3 by TGFβRI Critically Depends on PKCα\
(A and B) IB shows that TGFβ stimulation leads to SMAD2 and SMAD3 phosphorylation in WT cells yet is hindered in both *Prkca*^−/−^ cells (A) and cells preincubated with PKC LMWI (low-molecular-weight inhibitor) (B). CD4^+^ T cells were treated with TGFβ as indicated, and nuclear extracts (NEs) were generated.\
(C) Graphs represent the fold induction of normalized nuclear levels of selected TGFβ concentrations (0 and 5 ng/ml) of (p)SMAD2 (left) and (p)SMAD3 (right).\
(D) Transfection of the catalytically inactive kinase-dead K368R PKCα mutant (but not the WT) expression vector in Jurkat T cells repressed the expression of a SMAD2-3-dependent promoter luciferase reporter.\
(E) IB analysis confirmed equal total-protein expression levels of SMAD2 and SMAD3 between WT and *Prkca*^−/−^ CD4^+^ T cell lysates.\
(F and G) Reduced SMAD2-3 DNA binding to the SMAD-binding element (SBE) in both *Prkca*^−/−^ cells and PKC-LMWI-preincubated cells, as determined by electromobility shift assays (EMSA). CD4^+^ T cells were treated with TGFβ as indicated, and NEs were generated.\
(H) The graph represents the fold induction of normalized SMAD2-3-DNA-binding efficiency.\
(I) IL-2 levels were analyzed in Th17-cell-differentiated WT and *Prkca*^−/−^ cells. Data are from four independent experiments.\
(J) EMSA analysis of the binding capability of an *Il17a* minimal promoter oligonucleotide, containing a consensus STAT binding site and incubated with WT or *Prkca*^−/−^ NEs of cells that were stimulated as indicated (2 hr). Resting cells were used as unspecific controls.\
(K) Chromatin immunoprecipitation (ChIP) analysis (for 16 hr) of the binding capability of STAT3 to the minimal *Il17a* promoter in Th17-cell (TGFβ + IL-6)-primed, WT, or *Prkca*^−/−^ CD4^+^ T cells. Data are from two independent experiments.\
Representative blots are from two (J) or at least three (A, B, and E--G) independent experiments that yielded similar results. In (C) and (H), the results are presented relative to unstimulated WT levels and are normalized to the expression levels of DNA polymerase-δ, and data were pooled from at least three independent experiments. Error bars in (C), (D), (H), (I), and (K) represent the mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. (See also [Figure S5](#mmc1){ref-type="supplementary-material"}).](gr5){#fig5}

###### 

Clinical Parameters of MOG~35-55~-Induced EAE

  Genotype       Incidence (Score ≥ 0.5)   Onset Day (Mean ± SEM)   Maximum Score (Mean ± SEM)
  -------------- ------------------------- ------------------------ ----------------------------
  WT             100.00% (22/22)           10.89 ± 0.98             2.03 ± 0.22
  *Prkca*^−/−^   78.95% (15/19)            12.00 ± 1.39             0.80 ± 0.17^∗∗∗^

The results are shown as the mean ± SEM and indicate the total number of individual mice in three independent experiments. The following abbreviation is used: WT, wild-type. ^∗∗∗^p \< 0.001.

###### 

Transfer of MOG~35-55~-Specific Th17 Cells into WT 129sv Recipients

  Genotype       Incidence (Score ≥ 0.5)   Onset Day (Mean ± SEM)   Maximum Score (Mean ± SEM)
  -------------- ------------------------- ------------------------ ----------------------------
  Control        0% (0/2)                  NA                       NA
  WT             100% (4/4)                5.00 ± 0.41              2.25 ± 0.25
  *Prkca*^−/−^   100% (4/4)                14.00 ± 3.24^∗^          0.50 ± 0.00^∗∗∗^

The results are shown as the mean ± SEM and indicate the total number of individual mice. The following abbreviations are used: WT, wild-type; and NA, not applicable. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001.
